MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MOLECULAR PARTNERS AG
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$3.66+0.10 (+2.81%)
Close on Oct 19, 2026
Share price
−$0.26 (−6.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
MOLECULAR PARTNERS AG saw revenue fall 100.0% to CHF 0 over fiscal 2025. Free cash flow was -CHF 51.97M.
Revenue
CHF 0
-100.0% vs. a year earlier
Operating income
-CHF 58.12M
FY2025
Free cash flow
-CHF 51.97M
FY2025
EPS, diluted
-1.65 CHF
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CHF 0
- EPS, diluted
- -1.65 CHF
- Free cash flow
- -CHF 51.97M
Valuation needs the share price. It fills in once daily prices are connected and converted from CHF.
Eight years at a glance
Fiscal years 2018 to 2025, CHF
Revenue
CHF 0-100.0% YoY
Operating income
-CHF 58.12M
EPS, diluted
-1.65 CHF
Free cash flow
-CHF 51.97M
Reported period